Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: Comparison with factor XIIIa and CD34

British Journal of Dermatology

Volumn 157, Issue 2, 2007, Pages 319-324

  Kim, H J ^a   Lee, J Y ^a   Kim, S H ^a   Seo, Y J ^b   Lee, J H ^b   Park, J K ^b   Kim, M H ^c   Cinn, Y W ^c   Cho, K H ^d   Yoon, T Y ^a  

^a Chungbuk National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Dankook University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

CD34; Dermatofibroma; Dermatofibrosarcoma protuberans; Factor XIIIa; Immunohistochemistry; Stromelysin 3

Indexed keywords

BLOOD CLOTTING FACTOR 8A; CD34 ANTIGEN; STROMELYSIN 3;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ANTIGENS, CD34; DERMATOFIBROSARCOMA; DIAGNOSIS, DIFFERENTIAL; FACTOR XIIIA; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 11; TUMOR MARKERS, BIOLOGICAL;

EID: 34447511354     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08033.x     Document Type: Article

References (24)

1. Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. J Am Acad Dermatol 1993 28 : 613 17.
2. Aiba S, Tabata N, Ishii H et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. Br J Dermatol 1992 127 : 79 84.
3. Altman DA, Nickoloff BJ, Fivenson DP. Differential expression of factor XIIIa and CD34 in cutaneous mesenchymal tumors. J Cutan Pathol 1993 20 : 154 8.
4. Abenoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol 1993 15 : 429 34.
5. Goldblum JR, Tuthill RJ. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol 1997 19 : 147 53.
6. Cribier B, Noacco G, Peltre B, Grosshans E. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma vs. dermatofibrosarcoma protuberans. J Am Acad Dermatol 2002 46 : 408 13.
7. Kamino H, Jacobson M. Dermatofibroma extending into the subcutaneous tissue. Differential diagnosis from dermatofibrosarcoma protuberans. Am J Surg Pathol 1990 14 : 1156 64.
8. Calikoglu E, Augsburger E, Chavaz P et al. CD44 and hyaluronate in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. J Cutan Pathol 2003 30 : 185 9.
9. Kahn HJ, Fekete E, From L. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa. Hum Pathol 2001 32 : 50 6.
10. Hsi ED, Nickoloff BJ. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles. J Dermatol Sci 1996 11 : 1 9.
11. Kubo M, Ihn H, Yamane K, Tamaki K. The expression levels and the differential expression of transforming growth factor-β receptors in dermatofibroma and dermatofibrosarcoma protuberans. Br J Dermatol 2006 154 : 919 25.
12. Pedeutour F, Coindre JM, Sozzi G et al. Supernumerary ring chromosomes containing chomosome 17 sequences. A specific feature of dermatofibrosarcoma protuberans? Cancer Genet Cytogenet 1994 76 : 1 9.
13. Pedeutour F, Simon MP, Minoletti F et al. Ring chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995 55 : 2400 3.
14. Simon MP, Pedeutour F, Sirvent N et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997 15 : 95 8.
15. Wang J, Hisaoka M, Shimajiri S et al. Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription- polymerase chain reaction using archival formalin-fixed, paraffin-embedded tissues. Diagn Mol Pathol 1999 8 : 113 19.
16. Unden AB, Sandstedt B, Bruce K et al. Stromelysin-3 mRNA associated with myofibroblasts is overexpressed in aggressive basal cell carcinoma and in dermatofibroma but not in dermatofibrosarcoma. J Invest Dermatol 1996 107 : 147 53.
17. Thewes M, Worret WI, Engst R, Ring J. Stromelysin-3 (ST3): immunohistochemical characterization of the matrix metalloproteinase (MMP)-11 in benign and malignant skin tumours and other skin disorders. Clin Exp Dermatol 1999 24 : 122 6.
18. Wolf C, Chenard MP, Durand de Grossouvre P et al. Breast-cancer- associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 1992 99 : 870 2.
19. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992 14 : 455 63.
20. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993 9 : 541 73.
21. Basset P, Bellocq JP, Wolf C et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990 348 : 699 704.
22. Mari BP, Anderson IC, Mari SE et al. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem 1998 273 : 618 26.
23. Basset P, Wolf C, Chambon P. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues; a review. Breast Cancer Res Treat 1994 24 : 185 93.
24. Kim SH, Shin YK, Lee KM et al. An improved protocol of biotinylated tyramine-based immunohistochemistry minimizing nonspecific background staining. J Histochem Cytochem 2003 51 : 129 32.